Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy

Clinical Infectious Diseases

Volumn 52, Issue 10, 2011, Pages 1267-1275

  Gandhi, Monica ^a   Ameli, Niloufar ^b   Bacchetti, Peter ^c   Anastos, Kathryn ^e   Gange, Stephen J ^g   Minkoff, Howard ^f   Young, Mary ^h   Milam, Joel ^d   Cohen, Mardge H ⁱ   Sharp, Gerald B ^j   Huang, Yong ^b   Greenblatt, Ruth M ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Clinical Pharmacy ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f Downstate Health Sciences University   (United States)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^h GEORGETOWN UNIVERSITY   (United States)

ⁱ RUSH UNIVERSITY   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; CD4 ANTIGEN; RITONAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; AGED; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; FEMALE; HAIR ANALYSIS; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG MONITORING; FEMALE; HAIR; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MEDICATION ADHERENCE; MIDDLE AGED; MODELS, STATISTICAL; OLIGOPEPTIDES; PYRIDINES; TREATMENT OUTCOME;

EID: 79955450039     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir131     Document Type: Article

References (28)

1. Bisson GP, Gross R, Strom JB, et al. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS 2006; 20:1613-9. (Pubitemid 44162403)
2. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13(suppl 2):1-13. (Pubitemid 352019085)
3. Bertagnolio S, Kelley K, Hassani AS, et al. Surveillance of transmitted and acquired HIV drug resistance using WHO surveys in resourcelimited settings. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA 2011.
4. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr 2006; 43(suppl 1):S79-87. (Pubitemid 44885645)
5. Gandhi M, Greenblatt RM. Hair it is: the long and short of monitoring antiretroviral treatment. Ann Intern Med 2002; 137:696-7. (Pubitemid 35176105)
6. Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin ET, Messenkoff N. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom 2008; 22:3401-9.
7. Gandhi M, Ameli N, Bacchetti P, et al. Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS 2009; 23:471-8.
8. Liu A, Vittinghoff E, Gandhi M, et al. Validating measures of tenofovir drug exposure in a U.S. Pre-exposure prophylaxis trial. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2010.
9. Huang Y, Yang Q, Gandhi M, Greenblatt R, Gee W, Lin E. Sensitive analysis of ritonavir, lopinavir, atazanavir and efavirenz in human hair by LC/MS/MS for monitoring antiretroviral drug long-term exposure. American Association of Pharmaceutical Sciences (AAPS) Annual Meeting. San Diego, CA, 2007.
10. Yang Q, Liu A, Gandhi M, Greenblatt R, Gee W, Huang Y. LC/LC/MS Assay of Tenofovir in Human Hair for Pre-Exposure Prophylaxis. Association of Pharmaceutical Sciences (AAPS) Annual Meeting (New Orleans) 2010.
11. Huang Y, Yang Q, Koon K, Lei Y, Gee W, Lin ET, Greenblatt RM, Gandhi M. Microanalysis of the Antiretroviral Medication Nevirapine in Human Hair by LC/MS/MS for Monitoring Long-Term Drug Exposure. In press .
12. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. Epidemiology 1998; 9:117-25. (Pubitemid 28157608)
13. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials 2004; 5:74-9. (Pubitemid 38697081)
14. Beumer J, Bosman I, Maes R. Hair as a biological specimen for therapeutic drug monitoring. Int J Clin Pract 2001; 55:353-7. (Pubitemid 32707640)
15. Liu A, Gandhi M, Bacchetti P, et al. Validating hair as a biological marker of tenofovir drug exposure in HIV pre-exposure prophylaxis (PrEP). 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2011.
16. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials 2008; 9:238-46.
17. Lescure FX, Poirier JM, Meynard JL, et al. Factors predictive of virological failure on atazanavir in 310 HIV-infected patients. AIDS 2010; 24:1593-5.
18. Ray JE, Marriott D, Bloch MT, McLachlan AJ. Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol 2005; 60:291-9. (Pubitemid 41224137)
19. Cescon A, Cooper C, Chan K, et al. Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort. HIV Med 2010. Doi: 10.1111/j.1468-1293. 2010.00890.x.
20. Trotta MP, Cozzi-Lepri A, Ammassari A, et al. Rate of CD41 cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. Clin Infect Dis 2010; 51:456-64.
21. World Health Organization, Joint United Nations Program on HIV/ AIDS, United Nations Children's Fund. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report, September 2009. World Health Organization website. http://www.who.int/hiv/pub/ 2009progressreport/en/index.html. Accessed 21 November 2010.
22. Engsig FN, Omland LH, Larsen MV, et al. Risk of high-level viraemia in HIV-infected patients on successful antiretroviral treatment for more than 6 months. HIV Med 2010; 11:457-61.
23. Fabbiani M, Di Giambenedetto S, Ragazzoni E, et al. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. HIV Med 2010; 11:326-33.
24. Parienti JJ, Ragland K, Lucht F, et al. Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin Infect Dis 2010; 50:1192-7.
25. Gandhi M, Ameli N, Gange S, et al. Concentrations of efavirenz in hair correlate strongly with 24-hour intensive PK measurements and with virologic outcomes. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA:16-19 February 2010. Abstract N-154.
26. Hawkins C, Murphy RL. Management of antiretroviral failure and resistance in developing countries. Curr Opin HIV AIDS 2009; 4:538-44.
27. Reynolds S, Sendagire H, Newell K, et al. Routine viral load monitoring reduces the rate of genotypic resistance to commonly used ART in Uganda. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2011.
28. van Zyl GU, van Mens TE, McIlleron H, et al. Low lopinavir plasma or hair concentrations explain second line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr 2011. [Epub ahead of print].